CLASS ACTION UPDATE for CABA, FB and CELH: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you

CABA Shareholders Click Here: https://www.zlk.com/pslra-1/cabaletta-bio-inc-loss-submission-form?prid=26386&wire=1
FB Shareholders Click Here: https://www.zlk.com/pslra-1/meta-platforms-inc-loss-submission-form?prid=26386&wire=1
CELH Shareholders Click Here: https://www.zlk.com/pslra-1/celsius-holdings-inc-loss-submission-form?prid=26386&wire=1

* ADDITIONAL INFORMATION BELOW *

Cabaletta Bio, Inc. (NASDAQ:CABA)

This lawsuit is on behalf of persons and entities that purchased or otherwise acquired: (a) Cabaletta common stock pursuant and/or traceable to documents issued in connection with the Company's initial public offering conducted on or about October 24, 2019; and/or (b) Cabaletta securities between October 24, 2019 and December 13, 2021, both dates inclusive.
Lead Plaintiff Deadline : April 29, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/cabaletta-bio-inc-loss-submission-form?prid=26386&wire=1

According to the filed complaint, (i) top-line data of the Phase 1 Clinical Trial indicated that Cabaletta's lead product candidate, DSG3-CAART, had, among other things, worsened certain participants' disease activity scores and necessitated additional systemic medication to improve disease activity after DSG3-CAART infusion; (ii) accordingly, DSG3-CAART was not as effective as the Company had represented to investors; (iii) therefore, the Company had overstated DSG3-CAART's clinical and/or commercial prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Meta Platforms, Inc. (NASDAQ:FB)

FB Lawsuit on behalf of: investors who purchased March 2, 2021 - February 2, 2022
Lead Plaintiff Deadline : May 9, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/meta-platforms-inc-loss-submission-form?prid=26386&wire=1

According to the filed complaint, during the class period, Meta Platforms, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Apple's iOS privacy changes were having a material impact on Meta's ability to provide the kind of targeted advertising that its customers wanted and, as a result, customer ad spending was dropping precipitously; (2) Meta's mitigation efforts were either not properly implemented or ineffective; (3) measurement of ads was not accurate as mitigation efforts were failing; and (4) Meta did not have a plan in place to properly address the impact of the iOS privacy changes.

Celsius Holdings, Inc. (NASDAQ:CELH)

CELH Lawsuit on behalf of: investors who purchased August 12, 2021 - March 1, 2022
Lead Plaintiff Deadline : May 16, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/celsius-holdings-inc-loss-submission-form?prid=26386&wire=1

According to the filed complaint, during the class period, Celsius Holdings, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company had improperly recorded expenses for non-cash share-based compensation for second and third quarters of 2021; (2) as a result, the Company's financial statements for those periods would be restated, including to report a net loss for the third quarter of 2021; (3) there was a material weakness in Celsius's internal controls over financial reporting; and (4) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP